

Freedom of Information Request**Ref: UHB 18-088**

Date 10 April 2018

By Email

Dear Sir

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

- 1) How many Ovarian Carcinoma patients (any stage) have been diagnosed in the last 12 months?**
We can confirm there were 46 Ovarian Carcinomas diagnosed in the last 12 months.
- 2) How many stage III or IV Ovarian Carcinoma patients have received Chemotherapy for the first time in the last 12 months?**
We do not collect this information in a reportable format; therefore we do not hold this information.
- 3) Of these how many patients are on Platinum based therapy (Monotherapy or combination therapy)?**
We do not collect this information in a reportable format; therefore we do not hold this information.
- 4) How many stage III or IV Ovarian Carcinoma patients have been diagnosed as Platinum refractory (ie progression of disease whilst receiving Platinum therapy) or resistant (ie progression of disease within 6 months of last Platinum dose) in the last 12 months?**
We do not collect this information in a reportable format; therefore we do not hold this information.
- 5) How many patients with Stage III or IV Ovarian Carcinoma have been treated with the following treatments in the last 12 months?**
We do not collect this information in a reportable format; therefore we do not hold this information.
- 6) Of those how many are Platinum refractory or Platinum resistant?**
We do not collect this information in a reportable format; therefore we do not hold this information.

7) Within your Trust how many patients with Advanced Prostate Cancer have been treated in the past 12 months with the following treatments?

| Treatment | Patients |
|-----------------------|----------|
| Abiraterone (Zytiga) | 70 |
| Cabazitaxel (Jevtana) | 14 |
| Docetaxel (Taxotere) | 72 |
| Enzalutamide (Xtandi) | 80 |
| Radium-223 (Xofigo) | 134 |

8) How many patients being treated with Abiraterone or Enzalutamide and have been on this treatment for more than 1 year?

| Treatment | Patients |
|-----------------------|----------|
| Abiraterone (Zytiga) | 23 |
| Enzalutamide (Xtandi) | 25 |

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary
 University Hospitals Bristol NHS Foundation Trust
 Trust Headquarters
 Marlborough Street
 Bristol
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

██████████
 ██████████